Dr. Susie Barnes, BSc, MRCGP FFPM
Susie is a member of Royal College of General Practitioners and Faculty of Pharmaceutical Medicine in UK and a Fellow of the Faculty of Pharmaceutical Medicine, a Faculty of the Royal College of Physicians, UK
1996: Received her BSc (Hons) in Clinical Pharmacology and Biochemical Toxicology from Imperial College, London
1999: Received her medical degree from Imperial College, London and subsequently worked for the UK’s National Health Service for 10 years.
2009: Started to work in industry as a Physician at Servier Laboratories
2014: Joined GSK UK as Associate Medical Director
2016: Transferred to GSK Canada, firstly as Respiratory Medical Director followed by VP and Country Medical Director in 2017
July 2018: Transferred to GSK Japan as VP and Head of Medical Japan. She holds accountability as Country Medical Director since January 2019.
Stuart Sowder
Stuart Sowder, Vice President at Pfizer is currently responsible for compliance oversight for Asia, Pacific, African, and the Middle East. He is based in Tokyo. Previously, he led Pfizer’s External Medical Communications (EMC) group including several functions including Global Medical Information, Publications, Investigated Initiated Research and Medical Education and Pfizer’s Transparency functions and Field Based Medical Governance.
Stuart received a B.S. degree in Pharmacy from Rutgers University and his Doctorate of Pharmacy in 2010 from Shenandoah University. He earned a JD at New York Law School. He earned a MBA from Duke University’s Fuqua School of Business. Stuart joined Pfizer in 1997 after a career in hospital pharmacy at the Veteran’s Administration in Manhattan. Since joining Pfizer, he has held positions of increasing responsibility starting in the field force, moving on to Pfizer Outcomes Research, the Regional Medical Research Specialists, External Medical Communications, and now Compliance.
Andy Greenspan
Andrew is currently the Chief Global Medical Affairs Officer for Janssen.
Prior to this position, and as Vice President of Immunology Medical Affairs, Andrew was responsible for leadership and oversight of Immunology Medical Affairs activities supporting REMICADE®, SIMPONI®, SIMPONI ARIA®, STELARA® and TREMFYA® for a wide range of diseases, including Rheumatoid Arthritis, Crohn’s Disease, Ulcerative Colitis and Psoriasis.
Andrew joined Johnson & Johnson in 2003 taking on roles with increasing responsibilities, working across both Medical Affairs and Research & Development in Neuroscience, Immunology and Oncology. He has led numerous Phase 1 through 4 clinical studies and has co-authored over 35 peer reviewed journal articles. Andrew serves on the Board for Life Sciences Pennsylvania.
Andrew graduated Magna Cum Laude from Columbia University and earned his medical degree from Harvard Medical School. He completed his residency training in Internal Medicine at New York Hospital/Weill Cornell Medical College. Andrew enjoys mountain climbing, swimming, and playing the clarinet.
